Krystal Biotech, Inc. Appoints Andy Orth as Chief Commercial Officer
May 03, 2021 at 06:00 am EDT
Share
Krystal Biotech Inc. announced the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience, most recently in the role of Senior Vice President, Head of US Business at Alnylam Pharmaceuticals. In his role of Senior Vice President, Head of U.S. Region at Alnylam, Andy led the organization through multiple launches of rare disease genetic medicines and was responsible for leading the U.S. Business Account Teams, Market Access, Marketing, Patient Services and Operations. Previously, Andy served as Alnylam’s Vice President of Commercial Practice where he helped build out Alnylam’s global commercial capabilities.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
KRYSTAL BIOTECH, INC. 
